Stockscreener 앱 받기
0.2199
14.97%
-0.0387
AIM ImmunoTech Inc 주식(AIM)의 최신 뉴스
AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule — CEO Sees 'Significant Value-Inflection Period' Ahead - Stocktwits
Analysts’ Opinions Are Mixed on These Healthcare Stocks: AIM ImmunoTech (AIM) and Schrodinger (SDGR) - The Globe and Mail
Why Did AIM Stock Plummet 35% Today? - Stocktwits
Maxim Group Maintains AIM ImmunoTech(AIM.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article - The Manila Times
AIM's Ampligen-Treated Mouse Group Had 100% Ebola Survival - Stock Titan
Form 8K AIM ImmunoTech Inc For: 11 August By Investing.com - Investing.com Nigeria
Biodefense is force protection: Ready today, prepared for tomorrow - Breaking Defense
AIM ImmunoTech Releases Q2 2026 Financial Results - AlphaStreet
Form 8K AIM ImmunoTech Inc For: 10 August By Investing.com - Investing.com Australia
AIM ImmunoTech Q2 loss widens to $3.8M, EPS misses estimates - scanx.trade
AIM ImmunoTech Reports Completion of Phase 2 Ampligen Dosing in Metastatic Pancreatic Cancer Trial, Advances Phase 3 Planning - Quiver Quantitative
AIM ImmunoTech Reports Q2 2026: $9.9M Cash, $3.8M Net Loss - TradingView
AIM Completes Pancreatic Cancer Study Dosing; Phase 3 Planned - Stock Titan
AIM ImmunoTech (NYSE: AIM) returns to positive equity after new financings - Stock Titan
AIM ImmunoTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
AIM ImmunoTech Inc (AIM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 8K AIM ImmunoTech Inc For: 6 August By Investing.com - Investing.com Nigeria
AIM ImmunoTech signs $1.5 million manufacturing agreement with Sterling Pharma - Investing.com
AIM ImmunoTech (AIM) inks $1.5M manufacturing pact for Ampligen - Stock Titan
AIM ImmunoTech (AIM) Climbs 7.98% as Biotech Micro-Cap Tests Key Resistance at $0.29PCR Spike - dars.gov.et
AIM ImmunoTechDuripanc Overall Survival En - Moomoo
AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point - Yahoo Finance
AIM ImmunoTech Inc (AIM) Institutional Confidence - TradingKey
AIM ImmunoTech Inc (AIM) Cash Flow - TradingKey
AIM|AIM ImmunoTech Inc|Price:0.254|Chg%:+0.005 - TradingKey
AIM ImmunoTech Inc (AIM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AIM ImmunoTech Inc (AIM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AIM ImmunoTech Inc (AIM) Balance Sheet - TradingKey
AIM|AIM ImmunoTech Inc|Price:0.241|Chg%:-0.009 - TradingKey
AIM ImmunoTech Inc (AIM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aim Immunotech Inc. (AIM) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Aim Immunotech Inc. (AIM) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
AIM ImmunoTech Inc. Revenue Breakdown – AMEX:AIM - TradingView
Zacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive Surgical - Yahoo Finance
AIM ImmunoTech Inc. (AIM) Stock Price, News, Quote & History - Yahoo! Finance Canada
AIM ImmunoTech Inc. (AIM) stock price, news, quote and history - Yahoo Finance Australia
AIM ImmunoTech Q1 2026 Earnings: EPS Misses Estimates as Company Continues Clinical DevelopmentRevenue Report - dars.gov.et
Frontier tech research, news & data - MLQ.ai
AIM ImmunoTech(AIM) Stock Options Chain | Quotes & News - Moomoo
AIM ImmunoTech Stockholders Approve Key Equity Proposals - TipRanks
AIM ImmunoTech Inc. Announces Results of Shareholder Vote and Approves Reverse Stock Split – SEC 8-K Filing Highlights - Minichart
Shareholders at AIM ImmunoTech (NYSE: AIM) approve >19.99% issuances and reverse split - Stock Titan
AIM ImmunoTech shareholders approve stock issuance proposals at special meeting - Bitget
AIM ImmunoTech Q1 2026 Earnings: Wider-than-Expected Loss Highlights R&D Spending Amid Ongoing Pipeline ProgressReturn On Capital - dars.gov.et
AIM News | AIM IMMUNOTECH INC (NYSEARCA:AIM) - ChartMill
AIM Should I Buy - Intellectia AI
AIM ImmunoTech (AIM) Hovers Near Key Resistance Amid Minimal Price MovementFibonacci Retracement - dars.gov.et
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series - 富途牛牛
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program - The Manila Times
0.52%
0.07%
자본화:
|
볼륨(24시간):